Atelvia is an osteoporosis treatment drug owned by Apil. The active ingredient in Atelvia is risedronate sodium. The drug was first authorized for market use on October 8, 2010. This drug is available in tablet, delayed-release, and oral dosage forms. Atelvia has 3 drug patents, none of which have expired.
The generics of Atelvia could potentially be available after January 9, 2028. This release date is based on the expiry of the last patent in place on 2028-01-09.
Atelvia is primarily used for the treatment of osteoporosis in postmenopausal women. Its active ingredient, risedronate sodium, contributes to the drug's effectiveness by interfering with bone formation and breakdown in the body.
Atelvia has 3 active patents. The patent with the latest expiry date is the 'Dosage forms of risedronate,' which expires on January 9, 2028. This makes the possibilities for Atelvia generics to be released after this date. Below are the details of the patents: